Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy
Journal of Microbiology · 2026
DOI: 10.71150/jm.2510017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology, 2026. Verfasst von Heon Ju Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: CARBio Therapeutics Co., Ltd., Cheongju 28160, Republic of Korea. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, CD28 Antigens, Receptors, Chimeric Antigen, Claudins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of SMEs and Startups, Chungbuk Regional Innovation System & Education Center, Ministry of Education.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy holds significant potential for the treatment of solid tumors. However, immune suppression and tumor-specific barriers limit its application. Claudin 18.2 (CLDN18.2), a gastric lineage-specific tight junction protein highly expressed in gastric and pancreatic cancers, is a promising therapeutic target. In this study, we aimed to develop a next-generation tri-cistronic CLDN18.2-directed CAR-T cell platform that integrates a programmed cell death protein 1 (PD-1)/CD28 chimeric switch receptor with cyclophilin A (CypA). This platform sought to counteract PD-1–mediated immunosuppression and enhance T-cell activation and persistence. We generated CLDN18.2 CAR-T cells incorporating costimulatory inducible T-cell costimulator (ICOS) domains using lentiviral vector-based recombinant engineering. We further evaluated their cytokine release, cytotoxic activity, and safety profiles. In vitro, tri-cistronic CAR-T cells exhibited markedly increased interferon γ and tumor necrosis factor α secretion and enhanced cytotoxicity against CLDN18.2-positive gastric cancer cells compared with conventional CAR-T constructs. In vivo, these cells showed superior antitumor efficacy and sustained tumor regression without observable toxicity in xenograft gastric cancer models. Collectively, these findings demonstrate that the integration of PD-1/CD28 signaling and CypA within a tri-cistronic framework significantly reinforces CAR-T cell functionality and durability. This suggests strong clinical potential as a next-generation immunotherapy for solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CARBio Therapeutics Co., Ltd., Cheongju 28160, Republic of Korea.
- Translational Immunology Institute, Department of Medical Education, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
- Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Republic of Korea.
- Department of Biochemistry, Chungbuk National University, Cheongju 28644, Republic of Korea.
Förderung
- Ministry of SMEs and Startups
- Chungbuk Regional Innovation System & Education Center
- Ministry of Education
Zitieren
APA
Lee, H. J., Hwang, S. J., Jeong, E. H., Chang, M. H., Heo, B. Y., Kwon, J., Noh, Y., & Nah, J. (2026). Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy. Journal of Microbiology. https://doi.org/10.71150/jm.2510017
Vancouver
Lee HJ, Hwang SJ, Jeong EH, Chang MH, Heo BY, Kwon J, et al. Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy. Journal of Microbiology. 2026. doi:10.71150/jm.2510017
BibTeX
@article{Lee2026,
author = {Lee, Heon Ju and Hwang, Seo Jin and Jeong, Eun Hee and Chang, Mi Hee and Heo, Bu Yeon and Kwon, Jaeyul and Noh, Yoona and Nah, Jihoon},
title = {Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy},
journal = {Journal of Microbiology},
year = {2026},
doi = {10.71150/jm.2510017}
}
EUVIMED